Trials / Active Not Recruiting
Active Not RecruitingNCT06624228
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Risankizumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis
- Status
- Active Not Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 684 (actual)
- Sponsor
- UCB Biopharma SRL · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to compare the efficacy of bimekizumab versus risankizumab after 16 weeks of treatment in study participants with active psoriatic arthritis (PsA).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bimekizumab | Study participants will receive bimekizumab at pre-specified time points. |
| DRUG | Risankizumab | Study participants will receive risankizumab at pre-specified time points. |
| DRUG | Placebo | Study participants will receive placebo at pre-specified time points. |
Timeline
- Start date
- 2024-10-21
- Primary completion
- 2026-02-06
- Completion
- 2026-05-26
- First posted
- 2024-10-02
- Last updated
- 2026-04-13
Locations
127 sites across 11 countries: United States, Australia, Bulgaria, Canada, Czechia, Germany, Hungary, Japan, Poland, Spain, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06624228. Inclusion in this directory is not an endorsement.